The latest report by IMARC Group, titled “Non-Alcoholic Steatohepatitis (NASH) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“. The global non-alcoholic steatohepatitis (NASH) market size reached US$ 1.21 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.55 Billion by 2028, exhibiting a growth rate (CAGR) of 27.70% during 2023-2028.
Non-alcoholic steatohepatitis (NASH) is a liver condition characterized by inflammation and the accumulation of fat deposits in the liver, absent of excessive alcohol consumption. It is a severe form of non-alcoholic fatty liver disease (NAFLD) and can progress to more critical liver diseases such as cirrhosis and liver cancer if left untreated. NASH is often asymptomatic in its early stages, making it difficult to diagnose without specific tests. It typically affects individuals with obesity, type 2 diabetes, or high cholesterol levels. Due to its chronic nature, the management of NASH generally involves lifestyle changes and may require pharmacological intervention. Given the implications on long-term liver health and the increasing prevalence of NASH, there is a growing necessity for effective treatments and diagnostic methods within the healthcare industry.
Request Your Sample Report Now: https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market/requestsample
Non-Alcoholic Steatohepatitis (NASH) Market Trends and Drivers:
The global non-alcoholic steatohepatitis (NASH) market is primarily driven by the rising incidence of obesity and type 2 diabetes worldwide, both of which are risk factors for developing NASH. As awareness around the condition grows, more healthcare facilities are focusing on early diagnosis and treatment, which in turn fuels the market for NASH-related pharmaceuticals and diagnostic tools. Additionally, ongoing research and development (R&D) in the sector aims to bring more targeted treatments to the market, potentially offering better patient outcomes. In line with this, the increasing adoption of sedentary lifestyles has contributed to the uptick in NASH cases, prompting greater emphasis on preventative healthcare measures, thus propelling market growth. Furthermore, advancements in liver biopsy techniques and imaging studies are providing a positive thrust to the diagnosis sector within the industry, thereby contributing to market growth.
Report Segmentation:
The report has segmented the market into the following categories:
Drug Type Insights:
- Vitamin E and Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cenicriviroc
- Others
Disease Cause Insights:
- Hypertension
- Heart Disease
- High Blood Lipid
- Type 2 Diabetes
- Obesity
Sales Channel Insights:
- Hospital Pharmacy
- Online Providers
- Retail Pharmacy
End User Insights:
- Hospitals
- Clinics
- Homecare Settings
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- Algernon Pharmaceuticals
- Galmed Pharmaceuticals Ltd
- Intercept Pharmaceuticals Inc.
- Zydus Lifesciences Limited
Explore full report with table of contents: https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us
IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal
